Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Purified / Lyophilized / Endotoxin Level: Less than 1.0 EU/µg protein (determined by LAL method).
IGFBP7 / TAF
Met 1-Leu 282
HEK 293 Cells
Greater than 85% by SDS-PAGE
Measured by its binding ability in a functional ELISA. 1. Immobilized IGFBP7-Fc at 20 µg/ml (100 µl/well) can bind biotinylated human IGF2-nusa. The EC50 of biotinylated human IGF2-nusa is 0.06 µg/ml. 2. Immobilized human CCL21 at 2 µg/ml (100 µl/well) can bind human IGFBP7-Fc with a linear ranger of 0.16-4 µg/ml.
Less than 1.0 EU/µg protein (determined by LAL method).
Lyophilized from sterile PBS, pH 7.4
Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
IGFBP7 / TAF is a member of the insulin-like growth factor (IGF)-binding protein (IGFBP) family. IGFBPs bind IGFs with high affinity, and regulate IGF availability in body fluids and tissues and modulate IGF binding to its receptors. This protein binds IGF-I and IGF-II with relatively low affinity, and belongs to a subfamily of low-affinity IGFBPs. It also stimulates prostacyclin production and cell adhesion.